Clinical trials: Dosimetry
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers
The purpose of this study is to evaluate [11C] JNJ-42491293 as a PET ligand in healthy adult volunteers.
- Trial name
- NCT01359852
- Testing
- [11C] JNJ-42491293, [11C] JNJ-42491293 + JNJ-40411813
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Prostate Cancer Recurrent, Prostate Cancer
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with tissue histopathology in intermediate to high…
- Trial name
- NCT03444844
- Testing
- Ga-68 P16-093 PET/CT scan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Five Eleven Pharma, Inc.
Non-Hodgkin Lymphoma
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed…
- Trial name
- NCT02657447
- Testing
- Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2
- Where
- Germany
- Sponsor
- Nordic Nanovector
Relapsing-remitting Multiple Sclerosis (rrMS)
Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).
To evaluate the safety, bio-distribution, and radiation dosimetry; and to optimize the Imaging Protocol of GEH120714 (18F) Injection.
- Trial name
- NCT01738347
- Testing
- Arm 1 - GEH120714 (18F) Injection
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese…
- Conditions
- Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer
- Trial name
- ZIRDOSE-CP (NCT05861778)
- Testing
- 89Zr-Girentuximab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Liver Metastases
AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer
The purpose of the study is to assess a new treatment for patients with liver tumor metastases from colorectal cancer. The treatment has never been used in humans before.
- Trial name
- NCT02053324
- Testing
- AvidinOX/ST2210
- Where
- 4 sites in Austria, Italy
- Volunteers
- 14 people
- Sponsor
- Alfasigma S.p.A.
Arthritis, Rheumatoid
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
A prospective, open-label, single center, study to evaluate pharmacokinetics and dosimetry of intravenously injected Tc 99m tilmanocept at three mass doses (50 µg, 200 µg, and 400 µg) radiolabeled with 10 millicuries (mCi) Tc 99m.
- Trial name
- NCT03241446
- Testing
- Tilmanocept
- Sponsor
- Navidea Biopharmaceuticals
Multiple Myeloma
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma
Multiple myeloma is a disease that resides primarily in the bone and has shown to be sensitive to radiation. Administration of a radiotherapy agent that targets the bone, such as Holmium-166-DOTMP, in conjunction with melphalan…
- Trial name
- NCT00039754
- Testing
- Holmium-166-DOTMP
- Sponsor
- Poniard Pharmaceuticals
Colorectal Neoplasms
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of residual colorectal cancer following recent surgery.
- Trial name
- NCT00041691
- Testing
- hMN14 (labetuzumab)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Prostate Cancer, Prostatic Cancer
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms
- Trial name
- NCT00643617
- Testing
- CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk
- Where
- 18 sites in United States
- Volunteers
- 307 people
- Sponsor
- Accuray Incorporated
Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative…
- Trial name
- NCT07117214
- Testing
- [68Ga]Ga-DWJ155
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)
This study will estimate the radiochemical and radiation safety and assess the efficacy of [18F]MK-3328, a novel positron emission tomography (PET) tracer.
- Trial name
- NCT00954538
- Testing
- [18F]MK-3328
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Glioblastoma Multiforme
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody.
- Trial name
- NCT00509301
- Testing
- 131-I-chTNT-1/B MAB
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Peregrine Pharmaceuticals
Ovarian Cancer, Lung Cancer
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-EVS459 and the safety and imaging properties of [68Ga]Ga-EVS459 in patients aged ≥ 18 years with advanced…
- Trial name
- NCT06376253
- Testing
- [68Ga]Ga-EVS459, [177Lu]Lu-EVS459
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Solid Tumors
A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases
- Trial name
- NCT07249892
- Testing
- BPR-6023021 for injection
- Where
- China
- Volunteers
- 195 people
- Sponsor
- Chengdu Syncor Pharmaceutical Co., Ltd.
Pancreatic Cancer
Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2*…
- Trial name
- NCT06129422
- Testing
- NMK89
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Nihon Medi-Physics Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
Study With [225Ac]Ac-FL-020 in mCRPC Participants
The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of [225Ac]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- ProTACT (NCT06492122)
- Testing
- [225Ac]Ac-FL-020, Blood samples for PK, [111In]In-FL-020
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 50 people
- Sponsor
- Full-Life Technologies UK Limited
Advanced Solid Tumors
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.
- Trial name
- NCT06925581
- Testing
- HRS-6768
- Where
- 2 sites in China
- Volunteers
- 84 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Coronary Artery Disease (CAD), Myocardial Ischemia
A Study of XTR004 Radiotracer in Healthy Volunteers
XTR004 is a 18F-labeled myocardial perfusion positron emission tomography tracer use to measure myocardial perfusion and myocardial blood flow.
- Trial name
- NCT05195879
- Testing
- XTR004
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group